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It has been over seventeen years since the scientific definition of probiotics was crafted,
along with guidelines ensuring the appropriate use of the term. This definition is now
used globally, yet on a consistent basis scientists, media and industry misrepresent
probiotics or make generalized statements that illustrate a misunderstanding of their
utility and limitations. The rate of discovery of novel organisms with potentially
therapeutic benefit for both human and environmental health is progressing at an
unprecedented rate. However, the term “probiotic” is often misapplied to describe
any microbe with plausible therapeutic utility in the human host. It is argued that
strict compliance to the scientific definition of the term “probiotic” and avoidance of
generalizations to the whole field of probiotics based upon studies of one product, will
help advance the development and validation of microbial therapies, and applications to
improve human health.
Keywords: human microbiome, probiotics, scientific definition, stewardship, requirements, human health,
microbial therapies, translational microbiology
INTRODUCTION
In 2001, an Expert Panel was convened at the request of the Food and Agriculture Organization
of the United Nations, and supported by the World Health Organization, to clarify the definition
of probiotics. The resultant publication defined probiotics as “Live microorganisms which when
administered in adequate amounts confer a health benefit on the host” (FAO/WHO, 2002). In 2014,
a consensus panel reiterated the definition, with one small change replacing “which” with “that”
(Hill et al., 2014).
Since 2001, scientific investigation of probiotics has grown substantially. As of February 11, 2019,
there were 20,315 papers indexed to the term “probiotic” compared to 760 papers prior to 2001.
Commercially, the sales of probiotics are over $40 billion and are projected to reach over $64 billion
by 2023 (Global Market Insights, 2016).
The probiotic field represents the translational potential of microbiology to humans and animals.
Despite well characterized mechanisms for microbial therapies to affect a number of organ systems
in the host, confusion persists around the precise conditions necessary for a single microbe or
microbial consortia to claim probiotic effect (verb) or qualify as a probiotic (noun). Specifically,
a set of guidelines stipulates the need for both microbial strain designation and for at least one
human study to be performed on the target host to be considered probiotic (FAO/WHO, 2002).
Liberal and loose usage of the term has resulted in confusion and as a result, probiotics have
collectively garnered a degree of global skepticism. The aim of this article is to clarify the term
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probiotics and urge researchers to employ precision and
consistency in both their investigations and communication of
data pertaining to microbes for human health.
ILLUSTRATING THE PROBLEMS
A physician wanting to provide a patient with advice on
preventing traveler’s diarrhea (TD) may have referenced
a recent meta-analysis by Bae (2018) regarding the use of
probiotics as a treatment. This publication used a seemingly
appropriate inclusion criteria of double-blind, placebo-
controlled, randomized human trials with TD as an outcome,
and various statistical methods to conclude that probiotics were
efficacious in preventing TD. However, a closer look at the listed
interventions shows one study that utilized dead lactobacilli and
two other studies that included the administration of prebiotics.
Caution must be exercised when interpreting such data, given
that probiotics must be live (FAO/WHO, 2002; Sanders et al.,
2007), and the definition of a prebiotic is “a substrate that is
selectively utilized by host microorganisms conferring a health
benefit” (Gibson et al., 2017).
Confusion within the field is not restricted to meta-analyses.
Conclusions are often advanced based on improperly designed
intervention studies that extrapolate broad generalizations from
a limited data set. Several examples are worth citing. One study
concentrating on the use of probiotics in acute pancreatitis
suggested that they contributed to bacterial translocation and
enterocyte damage in organ failure (Besselink et al., 2004, 2009).
Yet, there is no direct evidence that the administered strains
were the cause (Reid et al., 2008). Aside from the issue of
whether or not this is an appropriate clinical setting to administer
extrinsic living bacteria, the study’s conclusion has been enlarged
to imply that any or all probiotics might adversely impact all
patients with pancreatitis. Nine years later, that initial study
has been fully reassessed concluding that probiotics are not
contraindicated in pancreatitis. The prior negative outcomes
were related to unexpected lactic acidosis from the fermentation
of carbohydrates (Bongaerts and Severijnen, 2016). Indeed, this
more recent study recommended starting probiotics immediately
upon diagnosis, massively increasing the probiotic dose, and
limiting fermentable carbohydrates.
To avoid unwarranted damage to the reputation of probiotics,
stringent testing and careful clinical guidelines are imperative
in the treatment and management of high risk adults and
children (Sanders et al., 2016). Not all centers have avoided
use of probiotics in seriously ill patients as a result of
the pancreatitis paper, and indeed one site has reported
substantial benefits in treating seriously ill trauma patients with
probiotics or synbiotics (Giamarellos-Bourboulis et al., 2009).
Furthermore, there is clear evidence of probiotics as useful
in preventing necrotizing enterocolitis in premature, low-birth
weight babies which is certainly a critically ill patient sub-set
(Patel and Underwood, 2018).
Another pertinent example of the over interpretation of
limited data is a recent study conducted on 34 patients suffering
from “brain fogginess,” which is a set of presentations including
impaired concentration, confusion, and poor short-term memory
(Rao et al., 2018). Based on the observation that consumption
of fermented food or commercially available microbial products
was a shared trait amongst the patients reporting brain fog, the
study implied that all probiotics could be causative agents of
brain fogginess. While the definition of probiotics accommodates
strains of any taxa, it is unlikely that these included the
Streptococcus, Staphylococcus, Neisseria, or Hemophilus, which
were the primary organisms detected by culture in the duodenal
aspirates. Furthermore, 68% of the cohort presented with small
intestinal bacterial overgrowth (SIBO) and there were no data to
verify patients were acidotic; a crucial linkage considering many
lactobacilli and all bifidobacteria only produce L-lactate and not
D-lactate (Vitetta et al., 2017; Petrova et al., 2018; Quigley et al.,
2018). In the future, appropriate trial design can strengthen the
field by moving away from observational and correlative data
sets. In this case, the study concluded that probiotics may be
causative of brain fog on the observation that antibiotic therapy
alleviated symptoms of brain fog, whereas a more appropriately
designed study would have split the patients after antibiotic
therapy into two groups, and upon reintroduction of probiotics in
a defined cohort, compared the emergence of symptoms against
the antibiotic-treated control.
In a third example, a recent study suggesting probiotics impair
naïve microbiota recovery after antibiotic therapy concluded
that probiotics may be harmful to the gut microbiota when
administered after antibiotic use (Suez et al., 2018). In this
instance, Suez et al. (2018) performed an intervention study
on healthy subjects given high doses of metronidazole and
ciprofloxacin. The subjects received evacuation therapy twice
in 28 days so that intestinal samples could be acquired. Based
on the observation that 10–15 species had a longer recovery
time compared to spontaneous recovery and autologous fecal
microbiota transplantation (aFMT), the study put forward the
thesis that probiotic consumption may present latent danger
to the gut microbiome and, by extension, the host. There
are serious limitations to asserting broad generalizations from
one narrow data set to the field as a whole. In this case,
two subsequent human studies published within a month
of the Suez et al. (2018) study and a second report from
that group (Zmora et al., 2018) presented alternative data
(De Wolfe et al., 2018; Korpela et al., 2018). The first
demonstrated that probiotic supplementation restored normal
microbiota composition and function in antibiotic-treated and
cesarean-born infants. A second study examined a different
microbial preparation and its effect on microbiome recovery
after antibiotic therapy (De Wolfe et al., 2018). Notably, the
microbial intervention contained a 700% higher dosage and
was administered for twice the intervention period as the
Suez et al. (2018) intervention with opposite data showing
improved microbiome alpha-diversity in the “probiotics” group
as measured by the Shannon diversity index, a heterogeneity
measure that combines richness and evenness components of
microbial diversity (De Wolfe et al., 2018). It is worth noting
that all three publications were released in the same month,
yet the results of one were extrapolated to the field as a
whole, hindering an open scientific dialog on the advantages or
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limitations of probiotics or their reproducible effects based on
strain specificity.
Relevantly, it is worth nothing that one should not rely on
metagenomic and 16s rRNA data as an endpoint alone, but
rather monitor clinical and functional outcomes, for example
an increase in short-chain fatty acid production and their direct
immunological effect on colonic Treg cells (Smith et al., 2013)
and other pathological processes (Cox et al., 2009; Ho et al.,
2018; Nagpal et al., 2018). Another effect of well characterized
probiotic strains is to confirm protection of the intestinal
epithelium, in some cases reversing damage caused by antibiotics
(Resta-Lenert and Barrett, 2006).
THE MINIMAL REQUIREMENTS FOR
THE EVALUATION OF AN EFFECTIVE
PROBIOTIC
As indicated in the original FAO/WHO (2002) report, there are
certain expectations required to call an organism “probiotic.”
These have been further clarified in 2014 (Hill et al., 2014), and
clearly must include:
The definition of probiotics as “Live microorganisms, that
when administered in adequate amounts, confer a health benefit
on the host.”
1. That microbes must be alive in an adequate number
when administered.
2. Strains must be identified genetically, classified using
the latest terminology, and designated by numbers,
letters, or names.
3. Appropriately sized and designed studies must be
performed to designate a strain as probiotic and using the
strain(s) on the host to which the probiotics are intended
(human, livestock, companion animal, etc).
4. Strains shown to confer a benefit for one condition may not
be probiotic for another application.
5. Strains that are probiotic for humans but are being used
in animal studies should be clearly designated as human
probiotics under experimental testing.
Fermented foods, prebiotics, fecal microbiota transplant, and
microbial strains of the same genus or species as documented
probiotic strains but have not undergone appropriate testing on
the target host should not be considered as probiotics based on
adherence to the scientific definition.
GUIDANCE FOR PHYSICIANS
Within the field of microbiome science, the rate of discovery
of novel organisms with potentially therapeutic benefit
for the human host is progressing rapidly. Emerging
research on microbial strains includes some with systemic
immunomodulatory activity (Geva-Zatorsky et al., 2017), the
prevention and treatment of food allergies (Kim et al., 2017;
Feehley et al., 2019), modulation of the gut-liver axis (Bajaj,
2019), production of neuroactive metabolites (Valles-Colomer
et al., 2019), and inhibitory activity against infectious microbes
in the gut (Kau et al., 2011), skin (Kober and Bowe, 2015), and
urogenital tract (Gottschick et al., 2017). Furthermore, microbes
are now understood as integral to an extensive number of
essential metabolic processes (Table 1) (Hentzer and Givskov,
2003; Ley et al., 2006; Abubucker et al., 2012; Karlsson et al., 2012;
Morgan et al., 2012; den Besten et al., 2013; Tang et al., 2013; Tang
and Hazen, 2014; Fiorucci and Distrutti, 2015; Hartstra et al.,
2015; Magnúsdóttir et al., 2015; McCabe et al., 2015; Neuman
et al., 2015; O’Mahony et al., 2015; Yano et al., 2015; Savidge, 2016;
Sonnenburg and Bäckhed, 2016; Thaiss et al., 2016; Yan et al.,
2016; Zeng et al., 2016; Blander et al., 2017; Koppel et al., 2017;
Weiss and Hennet, 2017; Desselberger, 2018; Fukui et al., 2018;
TABLE 1 | Physiological and metabolic processes influenced by the human microbiome.
Processes Reference
Enzymatic pathways, glycosaminoglycan degradation Abubucker et al., 2012; Koppel et al., 2017
Energy metabolism (short chain fatty acids, glucose) den Besten et al., 2013; Hartstra et al., 2015; Sonnenburg and
Bäckhed, 2016
Neurotransmitter production O’Mahony et al., 2015; Yano et al., 2015; Savidge, 2016
Vitamin absorption Magnúsdóttir et al., 2015
Regulation of bile acid metabolism, (deoxycholic and lithocholic acids,
bile salts)
Fiorucci and Distrutti, 2015; Weiss and Hennet, 2017
Endocrine and gut hormone regulation Neuman et al., 2015; Fukui et al., 2018
Adaptive immunity, mucosal and systemic immunity Thaiss et al., 2016; Desselberger, 2018
Cell proliferation, mucosal barrier protection, inflammation Morgan et al., 2012; Blander et al., 2017; Schirmer et al., 2018
Protection against pathogens Zeng et al., 2016; Zhang et al., 2018
Vascularization, tri-ethylamine associated atherosclerosis, tri-ethylamine
N-oxide (TMAO) production
Karlsson et al., 2012; Tang et al., 2013; Tang and Hazen, 2014
Bone mass McCabe et al., 2015; Yan et al., 2016
Appetite signaling, obesity Hentzer and Givskov, 2003; Ley et al., 2006
Metabolic transformation of xenobiotics (small molecules foreign to the
body)
Koppel et al., 2017
Frontiers in Microbiology | www.frontiersin.org 3 March 2019 | Volume 10 | Article 424
fmicb-10-00424 March 13, 2019 Time: 15:0 # 4
Reid et al. Probiotic Stewardship
Schirmer et al., 2018; Zhang et al., 2018). From these discoveries
will emerge new microbial-based interventions.
Therefore, it is expected that the misuse of the term “probiotic”
to describe any microbe with plausible therapeutic utility in
the human host may persist unless there is strict adherence to
the requirements of an exacting definition. To the extent that
physicians may require guidance for evaluating the merits of
current and future microbial preparations, three key elements in
determining the validity of a probiotic are proposed:
1. Evidence that the strain(s) has been tested in a randomized,
controlled or equivalent human trial, in either a
heterogeneous population or stratified based on defined
characteristics of host or microbial genomics.
2. The dose and viability in the product are equal to that of
the human trial(s).
3. Whole genome strain characterization and transparently
declared strain designation are provided.
If a strain is selected for a specific mechanism, such as being
able to upregulate gut barrier proteins, and is then tested in
humans and shown to improve gut barrier function leading to
a health benefit (Iemoli et al., 2012), then inclusion of that strain
at the tested dose would be expected to convey the same outcome
even in the presence of other strains. An example is B. breve BR03
being selected for immunomodulatory and gut barrier function
activities and consequently being found in a 300-person study
to increase Treg cells, or in 49 children with Celiac disease to
decrease TNFα production (Del Piano et al., 2010; Klemenak
et al., 2015).
Studies of the human microbiome have established that
despite significant interpersonal variation at the species level,
many core metabolic functions are maintained amongst
individuals in a population (Bogiatzi et al., 2018; Kleerebezem
et al., 2018; Wandro et al., 2018). Therefore, as the field
of personalized medicine gains traction, it is important that
proponents of individualized therapies clearly define the basis
for population stratification, and demonstrate efficacy for the
proposed personalized therapy in the specific subpopulation
being targeted. A more universal approach would entail
the discovery and validation of microbes with significant
and reproducible effects across a heterogeneous population.
Therapies under both a stratified and heterogeneous population
would meet the guidelines of probiotic, provided the impact on
human health is established in a controlled human trial.
FUTURE DIRECTIONS
Research investigating microbial administration to, or
modulation of, the human microbiome to improve health has
been progressing at a rapid rate since the term probiotics
was defined in 2001. It has been amplified by the Human
Microbiome Project and sustained by the interdisciplinary efforts
beyond microbiology that have contributed to the velocity of
microbiome research worldwide. It comes at a time where there
has never been a greater appreciation for the microbes that
inhabit life-forms and the planet. The potential to manipulate
these microbial ecosystems offers great hope for new preventive
and treatment options for many diseases. The idea that ingesting
or administering live microbes can serve therapeutic functions
is gaining prominence, but just as too many microbiome studies
in rodents and humans “oversell” their limited findings (Hooks
et al., 2018), too much misinformation has stemmed from misuse
of the probiotic term. It is hoped that the fundamental principles
outlined herein, that encourage adherence to a strict scientific
definition of “probiotics” and rigorous assessment of their actual
clinical outcomes will assert greater clarity and foster a deeper
understanding within this dynamic field.
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